

| | |
|-------------------------|--|
| 1. Record Nr. | UNINA9910492140903321 |
| Titolo | Image-guided management of COVID-19 lung disease // Robert L. Bard, editor |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] ©2021 |
| ISBN | 3-030-66614-X |
| Descrizione fisica | 1 online resource (163 pages) |
| Disciplina | 616.24 |
| Soggetti | Lungs - Diseases COVID-19 (Disease) - Alternative treatment Malalties del pulmó COVID-19 Imatges mèdiques Llibres electrònics |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Nota di contenuto | Intro -- Foreword -- Acknowledgments -- Contents -- Abbreviations -- 1: Covid-19 Safety Protocols and Protection -- 1.1 Introduction -- 1.2 Survivalism and the Global Demand for Disinfectants -- 1.3 Fighting Back with Bacteria-Killing Solutions -- 1.3.1 Types of Antimicrobial Sanitizers -- 1.4 Commercial Sanitizing for Prevention and Maintenance -- 1.4.1 Five Sanitizing Chemicals Identified Used in Hospitals [18, 19] -- 1.4.2 Sterilants and High-Level Disinfectants [19] -- 1.5 Personal Protective Equipment (PPE) -- 1.6 Sanitizing with UVC Light -- 1.6.1 History of UVC Applications -- 1.7 Epilogue -- 1.8 Summary -- References -- 2: CT Evaluation of COVID-19 Lung Disease -- 2.1 Introduction -- 2.2 Covid-19 Pneumonia -- 2.3 CT Data Image Acquisition -- 2.3.1 Radiologic Findings -- 2.3.2 Early Clinical Course -- 2.3.3 Comparison with Influenza Pneumonia -- 2.4 Image Guided Fusion Treatments -- 2.4.1 Bedside Lung and IVC Imaging -- 2.5 Image Guided Procedures -- 2.5.1 Pneumothorax After Puncture -- 2.6 Radiographic Limitations -- References -- 3: Lung Ultrasound in COVID-19 Disease -- 3.1 Introduction -- 3.2 |

Basics of Lung Ultrasound Examinations -- 3.2.1 A-lines -- 3.2.2 B-lines -- 3.3 Transducer Selection and Settings -- 3.3.1 Convex Transducers -- 3.3.2 Linear Transducers -- 3.3.3 Phased and Microconvex Transducers -- 3.4 Examination Procedure and Pathologies -- 3.5 Image Fusion -- 3.6 Findings -- 3.7 Conclusions -- References -- 4: Clinical Covid-19 Lung Imaging -- 4.1 Introduction -- 4.2 Findings -- 4.3 Approaches -- 4.4 Clinical Integration -- 4.5 Test Characteristics -- 4.6 Summary -- References -- 5: Pediatric Covid-19 Lung Ultrasound -- 5.1 Introduction -- 5.2 Role of Imaging in Pediatrics -- 5.3 How to Perform Pediatric Lung Ultrasound in the Time of COVID-19. 5.3.1 Ultrasonography Procedure 1 [40] -- 5.3.2 Ultrasonography Procedure 2 [31] -- 5.4 Ultrasonography Technique [29] -- 5.4.1 Other Specific Indications for the Images Acquisition Protocol -- 5.5 Lung Ultrasonography Findings -- 5.6 PIMS-TS and Point-of-Care Ultrasound -- 5.7 Conclusion -- References -- 6: Remote Diagnostics -- 6.1 Introduction -- 6.2 Testing Parameters -- 6.3 Advancing the Remote Scan Movement and Pre-hospital Ultrasound -- 6.4 Initializing the Remote Self-Screening Concept and Process -- 6.5 Remote Ultrasound Benefits for All Patient Types -- 6.5.1 MI: The Mechanical Index -- 6.5.2 TIS: The Soft-Tissue Thermal Index -- 6.6 Remote CT and Sonogram Fusion Diagnostics -- 6.6.1 Data -- 6.7 Salscan Project: Statement of Conclusion -- References -- 7: COVID-19 3D/4D Doppler Imaging -- 7.1 Introduction -- 7.2 Pathophysiology -- 7.3 Vascular Imaging Options -- 7.3.1 Microvessel Imaging -- 7.3.2 Chest Wall Imaging Limitations -- 7.3.3 Vascular Complications -- 7.4 Contrast-Assisted Sonography -- 7.4.1 Pleurisy -- 7.4.1.1 Color-Doppler Sonography of Focal Round Lesions -- 7.5 Large Lung Consolidation -- 7.5.1 Pneumonia -- 7.5.1.1 Color Doppler -- 7.5.1.2 Contrast-Assisted Sonography Pneumonia -- 7.5.1.3 Compressive Atelectasis -- 7.5.1.4 Obstructive Atelectasis -- 7.5.2 Space-Occupying Lesion of the Chest Wall -- 7.5.2.1 Color-Doppler Sonography -- 7.6 Quantifiable Digital Scanning and Image Guided Interventions -- 7.6.1 4D Imaging -- 7.6.2 3D/4D Doppler Histogram -- 7.6.3 Interventions in the Thorax: Indications -- 7.6.4 3D Lung Doppler -- 7.7 Summary -- References -- 8: Multimodality 3D Lung Imaging -- 8.1 Introduction -- 8.2 Stethoscopic Accuracy (Table 8.1) -- 8.3 Lung Sonogram Indications -- 8.3.1 Normal Lung Exam -- 8.3.2 A-Line Artifacts -- 8.3.3 B-Line Artifacts. 8.3.4 C-Line Artifacts -- 8.3.5 Lung Sliding -- 8.3.6 Lung Pulse -- 8.4 Pleural Ultrasound -- 8.4.1 Probe Positions -- 8.5 Consolidation -- 8.5.1 Pneumonia -- 8.5.2 Doppler Flow Patterns -- 8.6 Pneumothorax -- 8.7 Interstitial Syndrome -- 8.7.1 B-Line Pattern Recognition -- 8.8 Atelectasis -- 8.9 Pleural Effusion -- 8.10 Rib Cage -- 8.10.1 Probe Selection -- 8.10.2 Triage Imaging -- 8.11 Pitfalls in Scanning -- 8.12 Limitations of Lung Ultrasound -- 8.13 Limitations of Radiography -- 8.13.1 Best Practices -- 8.13.2 Equipment Specifications -- 8.14 Image Fusion -- 8.14.1 Registration Overview -- 8.14.2 Transformations -- 8.14.3 Interpolators -- 8.14.4 Metrics -- 8.14.5 Optimizers -- 8.15 Acute Care Considerations -- 8.15.1 Bedside IVC Imaging -- 8.16 Image Guided Procedures -- 8.16.1 Pneumothorax After Puncture -- 8.16.2 Pulmonary Fibrosis -- 8.16.3 High Resolution Pleural Imaging -- 8.16.4 Tissue Elastography -- 8.17 Future Directions -- 8.17.1 Algorithm Advances -- 8.17.2 Volumetric Imaging -- 8.17.3 Clinical Testing -- 8.18 Summary -- References -- 9: Respiratory Dynamics: Function and Breath Management -- 9.1 Introduction -- 9.2 Impact of Diseases on Respiratory Function -- 9.3 Probes for Respiratory Function --

9.3.1 Medical Assessment -- 9.3.2 Clinical Assessment -- 9.4 Exercises to Optimize Breath Management -- 9.5 Summary -- Appendix 1: Aerodynamic Resistance Exercises -- Appendix 2: Physical Stretches: Perform While Standing -- References -- 10: Respiratory Disease with SARS-COV2 Infection -- 10.1 Etiologic Agent, Disease Burden, Transmission, and Clinical Course -- 10.2 Pathogenesis and Clinical Course -- 10.2.1 Viral Entry Through Cell Surface ACE-2 Receptor and Predilection for Respiratory Infection -- 10.2.2 Role of ACE 2 Expression in Other Vital Organs in Overall Severity of Infection. 10.2.3 Inflammatory Immunopathogenesis and Coagulopathies -- 10.2.4 End Organ Damage with Evidence of Complement Activation -- 10.2.5 Clinical Symptoms and Signs -- 10.3 Clinical Assessment -- 10.3.1 Imaging -- 10.3.2 Therapies Under Evaluation for Managing Severe COVID-19 Disease -- 10.4 Clinical Perspective on Available Data -- References.
